Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-30T20:21:08.892Z Has data issue: false hasContentIssue false

Down syndrome, cardiac defect, embolisation, and COVID-19 vaccination: correspondence

Published online by Cambridge University Press:  02 May 2022

Rujittika Mungmunpuntipantip*
Affiliation:
Private Academic Consultant, Bangkok, Thailand
Viroj Wiwanitkit
Affiliation:
Dr DY Patil University, Pune, India
*
Author for correspondence: R. Mungmunpuntipantip, Private Academic Consultant, Bangkok, Thailand. Phone/Fax: 662256411366. E-mail: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Type
Letter to the Editor
Copyright
© The Author(s), 2022. Published by Cambridge University Press

Dear Editor, we would like to discuss on the publication “Concomitant pulmonary and neurological embolisation in a Down patient after SARS-CoV-2 vaccine: what is missing? Reference Di Molfetta, Volpe and Cesario1 ” Di Molfetta et al. mentioned that “Down patients affected by CHD are more prone to develop pulmonary vasculopathy than non-syndromic patients” and discuses on interrelationship with COVID-19 vaccination. The change of blood viscosity and alteration of coagulation system is a possible pathological process following COVID-19 vaccination. Reference Joob and Wiwanitkit2 The patient with underlying heart problem might have a risk for developing thrombotic disorder. However, it should recognise that there is also a possibility of concurrent medical problem that might lead to embolisation. For example, dengue might concomitantly occur in a COVID-19 vaccine recipient Reference Kebayoon and Wiwanitkit3 and might trigger embolisation. Reference Poletto, Cerruti and Spiezia4 Finally, it should discuss on the safety of the COVID-19 vaccine in a patient with underlying cardiac septal defect or vulvular disease. The structural defect in heart might interrupt flow of blood and might trigger thrombotic problem. Nevertheless, the recent report showed that there is no problem on safety of vaccination for patients with underlying rheumatic heart problem. Reference Sattui, Liew and Kennedy5

Conflicts of interest

None.

Authors contributions

RM 50%:

1a. Substantial contributions to study conception and design.

1b. Substantial contributions to acquisition of data.

1c. Substantial contributions to analysis and interpretation of data.

2. Drafting the article or revising it critically for important intellectual content.

3. Final approval of the version of the article to be published.

VW 50%:

1a. Substantial contributions to study conception and design.

1b. Substantial contributions to acquisition of data.

1c. Substantial contributions to analysis and interpretation of data.

2. Drafting the article or revising it critically for important intellectual content.

3. Final approval of the version of the article to be published.

References

Di Molfetta, A, Volpe, S, Cesario, M, et al. Concomitant pulmonary and neurological embolisation in a Down patient after SARS-CoV-2 vaccine: what is missing. Cardiol Young 2022; 13. DOI 10.1017/S1047951122000191, Online ahead of print.CrossRefGoogle Scholar
Joob, B, Wiwanitkit, V. Expected viscosity after COVID-19 vaccination, hyperviscosity and previous COVID-19. Clin Appl Thromb Hemost 2021; 27: 10760296211020833.CrossRefGoogle ScholarPubMed
Kebayoon, A, Wiwanitkit, V. Dengue after COVID-19 vaccination: possible and might be missed. Clin Appl Thromb Hemost 2021; 27: 10760296211047229.CrossRefGoogle Scholar
Poletto, F, Cerruti, L, Spiezia, L. Dengue fever as a rare cause of pulmonary embolism. J Thromb Thrombolysis 2020; 49: 690693.CrossRefGoogle ScholarPubMed
Sattui, SE, Liew, JW, Kennedy, K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021; 7: e001814.10.1136/rmdopen-2021-001814CrossRefGoogle ScholarPubMed